A remote command could one day send immune cells on a rampage against a malignant tumor. The ability to mobilize, from outside the body, targeted cancer immunotherapy inside the body has taken a step closer to becoming reality.
Bioengineers at the Georgia Institute of Technology have installed a heat-sensitive switch into T-cells that can activate the T-cells when heat turns the switch on. The method, tested in mice and published in a new study, is locally targeted and could someday help turn immunotherapy into a precision instrument in the fight against cancer.
Immunotherapy has made headlines with startling high-profile successes like saving former U.S. President Jimmy Carter from brain cancer. But the treatment, which activates the body’s own immune system against cancer and other diseases, has also, unfortunately, proved to be hit-or-miss.
“In patients where radiation and traditional chemotherapies have failed, this is where T-cell therapies have shined, but the therapy is still new,” said principal investigator Gabe Kwong. “This study is a step toward making it even more effective.”
Cancer is notoriously wily, and when T-cells crawl into a tumor, the tumor tends to switch off the T-cells’ cancer-killing abilities. Researchers have been working to switch them back on.
Laser, gold, and T-cells
Kwong’s remote control has done this in the lab, while also boosting T-cell activity.
In the study, Kwong’s team successfully put their remote-control method through initial tests in mice with implanted tumors (so-called tumor phantoms, specially designed for certain experiments). The remote works via three basic components.
First, the researchers modified T-cells, a type of white blood cell, to include a genetic switch that, when switched on, increased the cells’ expression of specific proteins by more than 200 times. That ability could be used to guide T-cells’ cancer-fighting activities.
The T-cells, with the switch off, were introduced into the tumor phantom which was placed into the mice. The tumor phantom also included gold nanorods, just dozens of atoms in size. The researchers shone pulses of a gentle laser in the near-infrared (NIR) range from outside the mouse’s body onto the spot where the tumor was located.
The nanorods receiving the light waves turned them into useful, localized mild heat, allowing the researchers to precisely warm the tumor. The elevated heat turned on the T-cells’ engineered switch.
This study honed the method and confirmed that its components worked in living animals. It was not the intention of the study to treat cancer yet, although undertaking that is the next step, which is already on its way.
“In upcoming experiments, we are implementing this approach to treat aggressive tumors and establish cancer-fighting effectiveness,” said Kwong, who is an assistant professor in the Wallace H. Coulter Department of Biomedical Engineering at Georgia Tech and Emory University.
The researchers published their results in the current edition of the journal ACS Synthetic Biology. The study’s first author was graduate research assistant Ian Miller. The research was funded by the National Institutes of Health, the National Science Foundation, the Burroughs Wellcome Fund, and the Shurl and Kay Curci Foundation.
Bioengineers have been able to do a lot with T-cells already when they’re outside of the body.
“Right now, we’re adept at harvesting a patient’s own T-cells, modifying to target cancer, growing them outside the body until there are hundreds of millions of them,” Kwong said. “But as soon as we inject them back into a patient, we lose control over the T-cells’ activity inside the body.”
The on-switch changes that.
Having an off-switch is also important. If T-cells were engineered to be always-on and hyper-activated, as they moved through the body, they could damage healthy tissue.
“There would be off-target toxicities, so you really want to pinpoint their activation,” Kwong said. “Our long-term goal for them is to activate site-specifically, so T-cells can overcome immunosuppression by the tumor and become better killers there.”
When the heat remote is turned off, so are Kwong’s engineered T-cells, because customary body temperatures are not high enough to activate their switch.
The switch is a natural safety mechanism in human cells that has evolved to protect against heat shock and turns on when tissue temperatures rise above the body’s normal operating range, which centers on 37 degrees Celsius (98.6 F). But the researchers re-fitted T-cells with the switch to make it turn on other functions, and it could be used to hyper-activate the cells.
The Georgia Tech bioengineers found that the switch worked in a range of 40 to 42 degrees Celsius (104 – 107.6 F), high enough to not react to the majority of high fevers and low enough to not damage healthy tissue nor the engineered T-cells.
“When the local temperature is raised to 45 degrees (113 F), some cells in our body don’t like it,” Kwong said. “But if heating is precisely controlled in a 40 to 42 degrees window with short pulses of the NIR light, then it turns on the T-cells’ switch, and body cells are still very comfortable.”
Immuno-goals and dreams
The researchers want to combine the switch with some additional cancer-fighting weapons they envision engineering into T-cells.
For example, secreted molecules called cytokines can boost immune cells’ ability to kill cancer, but cytokines, unfortunately, can also be toxic. “Our long-term goal is to engineer T-cells to make and release powerful immune system stimulants like cytokines on command locally and sparingly,” Kwong said.
In other studies, gently heated gold nanorods have been shown to kill tumors or hinder metastasis. But T-cell treatments could be even more thorough and, in addition, hopefully, one day give patients treated with them a long-lasting memory immune response to any recurrence of their cancer.
The Latest on: Targeted immunotherapy
via Google News
The Latest on: Targeted immunotherapy
- Sequence of Immunotherapy, Targeted Therapy, Radiation Therapy Influences Overall Survival in Melanoma Brain Metastases on February 20, 2019 at 12:50 pm
High 1-year overall survival (OS) rate was associated with stereotactic radiosurgery (SRS) followed by either immunotherapy or targeted therapy, according to results of a retrospective study of patien... […]
- Using Bristol-Myers’ popular leukemia drug to improve anti-PD-1 cancer immunotherapy on February 20, 2019 at 11:00 am
While many are using targeted therapies like Sprycel, some are pursuing different tactics. Researchers from the University of Southampton, for example, previously showed that combining an anti-PD-1 wi... […]
- First molecular test that selects immunotherapy for kidney cancer on February 19, 2019 at 1:15 pm
But immunotherapy is expensive ... successfully predict treatment response of kidney cancer patients to tyrosine kinase inhibitors, a type of targeted therapy. The results were published in 2015 in Eu... […]
- 'Exciting Times' With Immunotherapy for Kidney Cancer on February 19, 2019 at 8:56 am
The new combinations contain an immunotherapy and a targeted agent. New results with these combinations were presented here at the Genitourinary Cancers Symposium (GUCS) 2019 and were simultaneously p... […]
- New Immunotherapy Clinical Trial Targets Common Mesothelioma Protein on February 19, 2019 at 7:10 am
another immune-system inhibitor that has been targeted effectively in other malignancies, including non-small cell lung cancer. Earlier research has suggested the presence of VISTA within the mesothel... […]
- Combination of PARP inhibitor and immunotherapy results in tumor regression in SCLC mouse models on February 18, 2019 at 12:01 am
thus making SCLC cells susceptible to immunotherapy treatment. "I think the results from this study are really compelling because of the dramatic activity that we saw with the combination of adding a ... […]
- Why some brain tumors respond to immunotherapy on February 15, 2019 at 10:55 am
The study also suggests that glioblastoma patients with MAPK mutations may benefit more from immunotherapy if PD-1 inhibitors are combined with MAPK-targeted therapy, though the combination would ... […]
- Discussing the Future of Immunotherapy in Non-Small Cell Lung Cancer on February 14, 2019 at 6:51 am
As researchers have learned more about the mechanism behind the disease, targeted therapies for patients with EGFR ... You just spoke about bringing immunotherapy into EGFR mutations. Can you start by ... […]
- Sequential Immunotherapy, Targeted Therapy Linked to Cutaneous Adverse Events in Advanced Melanoma on February 11, 2019 at 11:58 am
Combination therapy with vemurafenib plus cobimetinib after immunotherapy may cause cutaneous adverse events (CAEs) in patients with BRAF-mutant metastatic melanoma. These findings are based on the re... […]
via Bing News